Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors

Clinical Cancer Research

Volumn 17, Issue 12, 2011, Pages 3943-3955

  Torres, Keila E ^a,d   Zhu, Quan Sheng ^a,d   Bill, Katelynn ^b,d,e   Lopez, Gonzalo ^b,d,e   Ghadimi, Markus P ^a,d   Xie, Xianbiao ^a,d   Young, Eric D ^a,d   Liu, Juehui ^a,d   Nguyen, Theresa ^a,d   Bolshakov, Svetlana ^a,d   Belousov, Roman ^a,d   Wang, Suizhau ^a,d   Lahat, Guy ^a,d   Liu, Jun ^b   Hernandez, Belinda ^a,d   Lazar, Alexander J ^c,d,e   Lev, Dina ^b,d,e  

^a Department of Surgical Oncology ^*  (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Sarcoma Research Center   (United States)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; SCATTER FACTOR RECEPTOR; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; XL 184;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; METASTASIS INHIBITION; METASTASIS POTENTIAL; MOUSE; NERVE SHEATH TUMOR; NONHUMAN; PERIPHERAL NERVE SHEATH TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SCID MOUSE; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT OUTCOME; TUMOR GROWTH; WESTERN BLOTTING;

ANILIDES; ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NERVE SHEATH NEOPLASMS; PHENOTYPE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959226237     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0193     Document Type: Article

References (49)

1. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, et al. Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer 2006;107:1065-74. (Pubitemid 44291156)
2. Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet 2002;39:311-4. (Pubitemid 34526349)
3. Zou C, Smith KD, Liu J, Lahat G, Myers S, Wang WL, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009;249:1014-22.
4. Ducatman BS, Scheithauer BW, Piepgras DG, Reiman HM, Ilstrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986;57:2006-21.
5. Wong WW, Hirose T, Scheithauer BW, Schild SE, Gunderson LL. Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 1998;42:351-60. (Pubitemid 28502782)
6. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;21:499-512. (Pubitemid 32959239)
7. Hueman MT, Schulick RD. Management of gastrointestinal stromal tumors. Surg Clin North Am 2008;88:599-614. (Pubitemid 351734511)
8. Rosen LS, Ashurst HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010;15:216-35.
9. Chao J, Chow WA, Somlo G. Novel targeted therapies in the treatment of soft-tissue sarcomas. Expert Rev Anticancer Ther 2010;10:1303-11.
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25. (Pubitemid 37493640)
11. Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41-59. (Pubitemid 34436961)
12. Cortner J, Vande Woude GF, Rong S. The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. EXS 1995;74:89-121.
13. Fukuda T, Ichimura E, Shinozaki T, Sano T, Kashiwabara K, Oyama T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48:757-62. (Pubitemid 28455692)
14. Rao UN, Sonmez-Alpan E, Michalopoulos GK. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol 1997;28:1066-70. (Pubitemid 27388108)
15. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-50. (Pubitemid 27451018)
16. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88. (Pubitemid 40270177)
17. Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025-37.
18. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 2001;61:5911-8. (Pubitemid 32769111)
19. Liu X, Newton RC, Scherle PA. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. Trends Mol Med 2010;16:37-45.
20. Liu X, Yao W, Newton RC, Scherle PA. Targeting the c-MET signaling pathway for cancer therapy. Expert Opin Investig Drugs 2008;17:997-1011.
21. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006;12:3657-60. (Pubitemid 44000247)
22. Krasnoselsky A, Massay MJ, DeFrances MC, Michalopoulos G, Zarnegar R, Ratner N. Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J Neurosci 1994;14:7284-90. (Pubitemid 24379740)
23. Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, et al. High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 2008;14:1015-24. (Pubitemid 351302546)
24. Su W, Gutmann DH, Perry A, Abounader R, Laterra J, Sherman LS. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004;45:297-306. (Pubitemid 38222258)
25. Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, et al. Large-scale molecular comparison of human Schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res 2006;66:2584-91.
26. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, et al. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 2009;8:1157-68.
27. Lahat G, Lazar A, Wang X, Wang WL, Zhu QS, Hunt KK, et al. Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. Clin Cancer Res 2009;15:2637-46.
28. Wang S, Ren W, Liu J, Lahat G, Torres K, Lopez G, et al. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 2010;16:2591-604.
29. McCarty MF, Baker CH, Bucana CD, Fidler IJ. Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol 2002;21:5-10.
30. Lopez G, Liu J, Ren W, Wei W, Wang S, Lahat G, et al. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma. Clin Cancer Res 2009;15:3472-83.
31. Torres K, Liu J, Young E, Huang F, Ghadimi M, Lusby K, et al. Expression of "drugable" tyrosine kinase receptors in MPNST: potential molecular therapeutic targets for a chemoresistant cancer. Histopathology. In press 2011.
32. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, et al. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-33. (Pubitemid 23023425)
33. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, et al. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55. (Pubitemid 30175676)
34. Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, Nupponen NN, Franssila K, Joensuu H. MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma. Am J Surg Pathol 2005;29:544-9. (Pubitemid 40411189)
35. Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R. XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010;13:112-21.
36. Joly A. Simultaneous blockade of VEGF and HGF receptors results in potent anti-angiogenic. EORTC Annual Meeting ; 2011; Brussels, Belgium; Abstract 104.
37. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-5.
38. Bottillo I, Ahlquist T, Brekke H, Danielsen SA, Van Den Berg E, Mertens F, et al. Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol 2009;217:693-701.
39. Mawrin C, Kirches E, Boltze C, Dietzmann K, Roessner A, Schneider-Stock R. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch 2002;440:610-5.
40. Zhou H, Coffin CM, Perkins SL, Tripp SR, Liew M, Viskoshi DH. Malignant peripheral nerve sheath tumor: a comparison of grade, immunophenotype, and cell cycle/growth activation marker expression in sporadic and neurofibromatosis 1-related lesions. Am J Surg Pathol 2003;27:1337-45. (Pubitemid 37185825)
41. Kong DS, Song SY, Kim DH, Joo KM, Yoo JS, Koh JS, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer 2009;115:140-8.
42. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol 2000;31:185-92. (Pubitemid 30090647)
43. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010;70:7580-90.
44. Saucier C, Khoury H, Lai KM, Peschard P, Dankort D, Naujokas MA, et al. The Shc adaptor protein is critical for VEGF induction by Met/ HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci U S A 2004;101:2345-50. (Pubitemid 38269314)
45. Hirsch FR, Mok TS, Borges V, Bunn PA Jr. Molecularly targeted therapy: when to stop and when to continue?Lancet Oncol 2010;11:709-11.
46. Kawachi Y, Xu X, Ichikawa E, Imakado S, Otsuka F. Expression of angiogenic factors in neurofibromas. Exp Dermatol 2003;12:412-7. (Pubitemid 36992415)
47. Wakelee HA, Gettinger SN, Engelman JA, Janne PA, West HJ, Subramaniam DS, et al. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol 2010;28suppl; abstr 3017.
48. Kurzrock R CE, Sherman SI, Pfister DG, Cohen RB, Ball D, et al. Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a phase I study of XL184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. J Clin Oncol 2010;28suppl; abstr 5502.
49. Wen P, Prados M, Schiff D, Reardon D, Cloughesy T, Mikkelsen T, et al. Phase 2 study of XL184 (BMS-907351), an inhibitor of MET, VEGFR2, and RET in patients with progressive glioblastoma. J Clin Oncol 2010:28suppl; abstr 2006.